≪英文≫

Reproductive organ involvement in women undergoing radical cystectomy for urothelial bladder cancer: a nationwide multicenter study.

Kato M, Taoka R, Miki J, Saito R, Fukuokaya M, Matsui Y, Yamamoto S, Matsue T, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Yamamoto S, Yasue K, Abe T, Nakanishi S, Hashine K, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Uchida J; Japan Urological Oncology Group.

Int J Clin Oncol. 2024 Oct 9. doi: 10.1007/s10147-024-02636-7. Online ahead of print. PMID:39379757

 

Development and validation of a model to predict the outcomes of radical cystectomy in patients with bladder cancer.

Fukuokaya W, Miki J, Taoka R, Saito R, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Nishiyama N, Nishiyama H, Kitamura H, Kimura T.

Int J Urol. 2024 Sep 18. doi: 10.1111/iju.15585. Online ahead of print. PMID: 39291802

 

The effect of human leukocyte antigen genotype on survival in advanced prostate cancer treated with primary androgen deprivation therapy: the KYUCOG-1401-A study.

Shiota M, Tanegashima T, Tatarano S, Kamoto T, Matsuyama H, Sakai H, Igawa T, Kamba T, Fujimoto N, Yokomizo A, Naito S, Eto M.

Prostate Cancer Prostatic Dis. 2024 Feb 17. doi: 10.1038/s41391-024-00808-0. Online ahead of print. PMID: 38368501

 

The contribution of the CRP/CD64 axis to renal cancer progression by inducing protumor activation of tumor-associated macrophages.

Pan C, Fujiwara Y, Yano H, Anami T, Ibe Y, Li L, Miura Y, Motoshima T, Esumi S, Yatsuda J, Hibi T, Kamba T, Komohara Y.

Clin Transl Immunology. 2024;13(11):e70013.

 

Regression and growth rates in androgen deprivation therapy for advanced castration-sensitive prostate cancer.

Blas L, Shiota M, Matsuyama H, Kamoto T, Enokida H, Fujimoto N, Sakai H, Igawa T, Kamba T, Yokomizo A, Naito S, Eto M.

World J Urol. 2024;42(1):604.

 

The efficacy of second-line tyrosine kinase inhibitor for patients with metastatic non-clear cell renal cell carcinoma following first-line immune-oncology combination therapy.

Fujita K, Matsushita Y, Toyoda S, Kojima T, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Nakamura E, Kaneko T, Kitano G, Motoshima T, Shiraishi, Kira S, Murashima T, Hara H, Matsumura, Nishiyama N, Miyake H, Kitamura H, Uemura H.

World J Urol. 2024;42(1):536.

 

Prognosis based on postoperative PSA levels and treatment in prostate cancer with lymph node involvement.

Tanegashima T, Shiota M, Kimura T, Takamatsu D, Matsui Y, Yokomizo A, Saito R, Morizane S, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Edamura K, Narita S, Yamaguchi T, Kasahara T, Hashimoto K, Kato M, Yoshino T, Akamatsu S, Matsukawa A, Kaneko T, Matsumoto R, Joraku A, Kato M, Saito T, Kato T, Tatarano S, Sakamoto S, Kanno H, Terada N, Nishiyama N, Kitamura H, Eto M; Japanese Urological Oncology Group.

Int J Clin Oncol. 2024;29(10):1586-1593.

 

A novel prognostic model of de novo metastatic hormone-sensitive prostate cancer to optimize treatment intensity.

Fujiwara H, Kubota M, Hidaka Y, Ito K, Kawahara T, Kurahashi R, Hattori Y, Shiraishi Y, Hama Y, Makita N, Tashiro Y, Hatano S, Ikeuchi R, Nakashima M, Utsunomiya N, Takashima Y, Somiya S, Nagahama K, Fujimoto T, Shimizu K, Imai K, Takahashi T, Sumiyoshi T, Goto T, Morita S, Kobayashi T, Akamatsu S.

Int J Clin Oncol. 2024;29(10):1574-1585.

 

A retrospective study of prognostic factors and prostate-specific antigen dynamics in Japanese patients with metastatic hormone-sensitive prostate cancer who received combined androgen blockade therapy with bicalutamide.

Tashiro Y, Akamatsu S, Ueno K, Kamoto T, Terada N, Hida T, Kurahashi R, Kamba T, Saito A, Lee T, Morita S, Kobayashi T.

Int J Clin Oncol. 2024;29(10):1564-1573.

 

 

Oncological outcomes of prophylactic urethrectomy at the time of radical cystectomy for bladder cancer: A nationwide multi-institutional study.

Miki J, Fukuokaya W, Taoka R, Saito R, Matsui Y, Hatakeyama S, Kawahara T, Matsuda A, Kawai T, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Nishiyama N, Nishiyama H, Kitamura H, Kimura T; Japan Urological Oncology Group.

Int J Urol. 2024;31(9):1009-1016.

 

Potential protumor function of CD74 in clear cell renal cell carcinoma.

Ezaki A, Yano H, Pan C, Fujiwara Y, Anami T, Ibe Y, Motoshima T, Yatsuda J, Esumi S, Miura Y, Kamba T, Komohara Y.

Hum Cell. 2024;37(5):1535-1543.

 

Prognostic impact of histological discordance between transurethral resection and radical cystectomy.

Matsuda A, Taoka R, Miki J, Saito R, Fukuokaya W, Hatakeyama S, Kawahara T, Fujii Y, Kato M, Sazuka T, Sano T, Urabe F, Kashima S, Naito H, Murakami Y, Miyake M, Daizumoto K, Matsushita Y, Hayashi T, Inokuchi J, Sugino Y, Shiga K, Yamaguchi N, Iio H, Yasue K, Abe T, Nakanishi S, Matsumura M, Fujii M, Nishihara K, Matsumoto H, Tatarano S, Wada K, Sekito S, Maruyama R, Nishiyama N, Nishiyama H, Kitamura H, Matsui Y; Japanese Urological Oncology Group.

BJU Int. 2024;134(2):207-218.

 

Effect of HLA Genotype on Anti-PD-1 Antibody Treatment for Advanced Renal Cell Carcinoma in the SNiP-RCC Study.

Tanegashima T, Shiota M, Fujiyama N, Narita S, Habuchi T, Fukuchi G, Takamatsu D, Oda Y, Miyake H, Takahashi M, Oya M, Tsuchiya N, Masumori N, Matsuyama H, Obara W, Shinohara N, Fujimoto K, Nozawa M, Ohba K, Ohyama C, Hashine K, Akamatsu S, Kamba T, Mita K, Gotoh M, Tatarano S, Fujisawa M, Tomita Y, Mukai S, Ito K, Tokunaga S, Eto M.

J Immunol. 2024;213(1):23-28.

 

Comparison of Cabozantinib and Axitinib as Second-line Therapy After Nivolumab Plus Ipilimumab in Patients With Metastatic Clear Cell Renal Cell Carcinoma: A Comparative Analysis of Retrospective Real-world Data.

Tomida R, Takahashi M, Matsushita Y, Kojima T, Yamana K, Kandori S, Bando Y, Nishiyama N, Yamashita S, Taniguchi H, Monji K, Ishiyama R, Tatarano S, Masui K, Matsuda A, Kaneko T, Motoshima T, Shiraishi Y, Kira S, Murashima T, Hara H, Matsumura M, Kitamura H, Miyake H, Furukawa J; Japanese Urological Oncology Group.

Clin Genitourin Cancer. 2024;22(3):102094.

 

Prognostication in Lymph Node-Positive Prostate Cancer with No PSA Persistence After Radical Prostatectomy.

Shiota M, Takamatsu D, Matsui Y, Yokomizo A, Morizane S, Saito R, Miyake M, Tsutsumi M, Yamamoto Y, Tashiro K, Tomida R, Narita S, Edamura K, Yamaguchi T, Hashimoto K, Kato M, Kasahara T, Yoshino T, Akamatsu S, Kaneko T, Matsukawa A, Matsumoto R, Joraku A, Saito T, Kato T, Kato M, Enokida H, Sakamoto S, Terada N, Kanno H, Nishiyama N, Kimura T, Kitamura H, Eto M; Japanese Urological Oncology Group.

Ann Surg Oncol. 2024;31(6):3872-3879.

 

Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan.

Nakanishi S, Fukushima Y, Inokuchi J, Hakariya T, Kakinoki H, Enokida H, Chikui K, Matsuoka H, Shin T, Mukai S, Kamba T, Eto M, Imamura R, Noguchi M, Igawa T, Haga N, Kamoto T, Fujimoto N, Saito S.

Int J Urol. 2024;31(5):484-491.

 

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma.

Choueiri TK, Tomczak P, Park SH, Venugopal B, Ferguson T, Symeonides SN, Hajek J, Chang YH, Lee JL, Sarwar N, Haas NB, Gurney H, Sawrycki P, Mahave M, Gross-Goupil M, Zhang T, Burke JM, Doshi G, Melichar B, Kopyltsov E, Alva A, Oudard S, Topart D, Hammers H, Kitamura H, McDermott DF, Silva A, Winquist E, Cornell J, Elfiky A, Burgents JE, Perini RF, Powles T; KEYNOTE-564 Investigators.

(Murakami Yoji is indicated in List of Investigators, Supplementary Appendix.)

N Engl J Med. 2024;390(15):1359-1371.

 

GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.

Yokomizo A, Shiota M, Morokuma F, Eto M, Matsuyama H, Matsumoto H, Kamoto T, Terada N, Kawahara K, Enokida H, Tatarano S, Fujimoto N, Higashijima K, Sakai H, Hakariya T, Igawa T, Suekane S, Kamba T, Sugiyama Y, Kishimoto J, Naito S.

Int J Urol. 2024;31(4):362-369.

 

Effects of thienopyridine class antiplatelets on bleeding outcomes following robot-assisted radical prostatectomy.

Kubota M, Kawakita M, Yoshida S, Kimura H, Sumiyoshi T, Yamasaki T, Okumura K, Yoshimura K, Matsui Y, Sugiyama K, Okuno H, Segawa T, Shimizu Y, Ito N, Onishi H, Ishitoya S, Soda T, Yoshida T, Uemura Y, Iwamura H, Okubo K, Suzuki R, Fukuzawa S, Akao T, Kurahashi R, Shimatani K, Sekine Y, Negoro H, Akamatsu S, Kamoto T, Ogawa O, Kawakami K, Kobayashi T, Goto T.

(Kamba T is also indicated in Acknowledgement.)

Sci Rep. 2024;14(1):5847.

 

Overexpression of SerpinB9 in non-seminomatous germ cell tumors.

Anami T, Ibe Y, Li L, Komohara Y, Hirao H, Harada M, Yano H, Fujiwara Y, Motoshima T, Yatsuda J, Hibi T, Kamba T.

Med Mol Morphol. 2024;57(1):68-75.

 

Dysfunction of sinus macrophages in tumor-bearing host induces resistance to immunotherapy.

Anami T, Pan C, Fujiwara Y, Komohara Y, Yano H, Saito Y, Sugimoto M, Wakita D, Motoshima T, Murakami Y, Yatsuda J, Takahashi N, Suzu S, Asano K, Tamada K, Kamba T.

Cancer Sci. 2024;115(1):59-69.

 

≪和文≫

 

縦隔胚細胞腫瘍の１例

牧野耕，穴見俊樹，脊川卓也，倉橋竜磨，元島崇信，村上洋嗣，矢津田旬二，神波大己

西日泌尿. 2024;86(6):325-328.

 

尿道憩室癌の１例

田中聡，村上洋嗣，穴見俊樹，倉橋竜磨，元島崇信，矢津田旬二，神波大己

西日泌尿. 2024;86(6):305-310.

 

尿路上皮癌に対する免疫腫瘍療法

矢津田旬二，神波大己

西日泌尿. 2024;86(6):287-295.

 

脂肪を含有する Angiomyolipoma with epithelial cysts (AMLEC) の１例

坂梨壱成，矢津田旬二，穴見俊樹，倉橋竜磨，元島崇信，村上洋嗣，神波大己

西日泌尿. 2024;86(5):272-277.

 

ゲノム医療を念頭においた泌尿器科診療の在り方

倉橋竜磨，神波大己

西日泌尿. 2024;86(4):156-157. (Proceedings)

 

酸性尿酸アンモニウム結石の一例

清田明日香，脊川卓也，倉橋竜磨，元島崇信，村上洋嗣，矢津田旬二，杉山豊，神波大己

西日泌尿. 2024;86(3):136-139.

 

九州沖縄地区におけるガイドライン出版以前の陰茎癌診療の実態調査

山口隆大，呉屋真人，東島克佳，東武昇平，佐藤竜太，鑪野秀一，向井尚一郎，上村慶一郎，立神勝則，坪内和女，志田洋平，石井龍，酒井英樹，松岡弘文，羽賀宣博，江藤正俊，井川掌，賀本敏行，榎田英樹，秦聡孝，野口満，藤本直浩，斎藤誠一，神波大己

西日泌尿. 2024;86(3):98-107.